The tech and longevity markets are booming, driven by Mode’s EarnPhone, which saved users $325 million, and AI breakthroughs in drug discovery, personalised medicine, and diagnostics. The longevity sector, projected to hit $600 billion-$1 trillion by 2030, is seeing surging investments, with healthcare AI expected to attract $11.1 billion in 2024. Key players like Google DeepMind and Pfizer are advancing ageing research, highlighting the transformative potential of AI to extend lifespans and reshape healthcare while offering significant investment opportunities.

The global technology landscape is witnessing a seismic shift as Mode, a software company ranked #1 on this year's Deloitte 500 Fastest-Growing Companies list, reports an unprecedented 32,481% revenue growth from 2019 to 2022. With over $60 million in annual revenue, Mode is spearheading a revolution with its innovative "EarnPhone", a budget smartphone designed to help users earn and save money through everyday activities.

The EarnPhone has reportedly helped consumers collectively save and earn $325 million by engaging in activities like listening to music, gaming, and even charging their devices. This disruptive technology addresses the $1 trillion-plus market opportunity in mobile technology, marking the first major disruption to smartphones in 15 years.

Longevity technology: The next big investment opportunity

As global demographics shift, longevity technology is emerging as a critical area for innovation and investment. According to analysts, the number of people aged 80+ is projected to triple over the next 30 years, while centenarians are expected to increase tenfold. This significant demographic change is driving the demand for age-related therapies, personalised medicine, and preventative healthcare.

Raysa Bousleiman, VP of Life Science and Healthcare at SVB noted:

"It's no surprise AI is dominating the discourse, but one surprising takeaway is how fast it’s growing in healthcare. As compared to tech, it's growing two times as fast, not in terms of dollars or deal volume, but deal pace.”

AI’s role in transforming longevity technology

AI is playing a pivotal role in reshaping the longevity sector, with key applications across drug discovery, personalised medicine, diagnostics, and lifestyle optimisation. Recent breakthroughs in longevity-focused AI research include:

• Drug Discovery: AI algorithms are accelerating R&D and reducing costs, attracting significant interest from both startups and big pharma.
• Personalised Medicine: Clinics leveraging AI for data-driven, individualised treatments are expanding rapidly.
• Early Detection: AI-powered diagnostic tools are enabling the earlier identification of age-related diseases, improving outcomes.
• Lifestyle Technology: Wearables and apps offering health recommendations based on AI analysis are gaining popularity among consumers.

Resurgence in longevity investments

Despite a downturn in 2022, the longevity sector is experiencing renewed interest, supported by advancements in AI and biotech. In 2024, healthcare companies leveraging AI are expected to attract $11.1 billion in venture capital, building on the $7.2 billion invested in 2022.

High-profile milestones include the anticipated IPO of BioAge Labs, valued at $150 million, and significant funding rounds for firms like Rubedo, Alzheon, and Aeovian. The cumulative investment in longevity this year surpasses $700 million, reflecting a broader surge in the sector.

Tech and pharmaceutical giants are also recognising the potential of longevity tech. Google DeepMind’s AlphaFold AI model is advancing drug design, while its subsidiary Calico Labs focuses on understanding ageing biology. Pharma leaders like Pfizer and Novartis are expanding AI partnerships to enhance drug development and personalised care.

The future of longevity and AI

Experts predict the longevity market will grow at a compound annual growth rate (CAGR) of 20-25% in venture capital funding over the next decade, reaching a global market size of $600 billion to $1 trillion by 2030. The US is anticipated to account for approximately 40-45% of this growth.

For investors and innovators, the intersection of AI and longevity technology presents a transformative opportunity. This convergence could reshape healthcare delivery, extend human lifespan, and generate significant financial and societal benefits.

As industry momentum builds, those poised to succeed will be those who identify and invest in cutting-edge AI solutions that advance longevity research and application.